Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3)

BACKGROUND: Patients with psoriasis who have an inadequate response to one biologic may benefit from switching to a new biologic, such as ixekizumab, a high affinity monoclonal antibody that selectively targets interleukin (IL)-17A. OBJECTIVE: Our aim was to assess the response to ixekizumab in pati...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Am J Clin Dermatol
Auteurs principaux: Blauvelt, Andrew, Papp, Kim A., Griffiths, Christopher E. M., Puig, Luis, Weisman, Jamie, Dutronc, Yves, Kerr, Lisa Farmer, Ilo, Dapo, Mallbris, Lotus, Augustin, Matthias
Format: Artigo
Langue:Inglês
Publié: Springer International Publishing 2017
Sujets:
Original Research Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5884910/
https://ncbi.nlm.nih.gov/pubmed/28074446
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40257-016-0246-9
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires